Appropriateness of Initial Therapy
Dr. Motzer discusses his view on the appropriateness of the initial therapy for this nccRCC patient, including key factors he considers when deciding on initial treatment.
EP: 1.Initial Impression of Case
EP: 2.Appropriateness of Initial Therapy
EP: 3.Efficacy and safety of KEYNOTE-427
EP: 4.Efficacy and Safety and Emerging Combinations
EP: 5.Efficacy of Combination vs Single Agent Therapy
EP: 6.Managing Adverse Events
EP: 7.Risk/Benefits of Managing AEs with Combination Therapy
EP: 8.Quality of Life Preservation
EP: 9.Future Management of nccRCC
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
May 6th 2024The FDA is considering a subcutaneous nivolumab formulation for various solid tumors based on promising data from the phase 3 CheckMate -67T trial. A target action date has been set for February 28, 2025.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Tolerability Helps Decide Third-Line Treatment in Advanced RCC
April 30th 2024During a Case-Based Roundtable® Chandler H. Park, MD, led a discussion on the considerations physicians have when deciding on their treatment approach in the third line for patients with advanced renal cell carcinoma in the first article of a 2-part series.
Read More
Sustained Treatment-Free Survival in RCC Seen With Nivolumab and Ipilimumab
April 30th 2024Nivolumab monotherapy plus salvage nivolumab/ipilimumab demonstrated superior treatment-free survival rates among patients with advanced renal cell carcinoma, especially in patients with favorable risk profiles.
Read More
